Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Net Margin: 2010-2025

Historic Net Margin for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -13,591.00%.

  • Northwest Biotherapeutics' Net Margin fell 812713.00% to -13,591.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -9,735.75%, marking a year-over-year decrease of 528625.00%. This contributed to the annual value of -6,164.40% for FY2024, which is 283246.00% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Net Margin stood at -13,591.00% for Q3 2025, which was down 11.71% from -12,166.41% recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Net Margin registered a high of -1,255.34% during Q1 2023, and its lowest value of -18,551.78% during Q4 2021.
  • Its 3-year average for Net Margin is -6,987.70%, with a median of -5,921.43% in 2023.
  • Its Net Margin has fluctuated over the past 5 years, first soared by 289,945,337bps in 2021, then plummeted by 1,220,757bps in 2022.
  • Northwest Biotherapeutics' Net Margin (Quarterly) stood at -18,551.78% in 2021, then soared by 1,381,174bps to -4,740.03% in 2022, then surged by 152,251bps to -3,217.53% in 2023, then crashed by 911,840bps to -12,335.93% in 2024, then plummeted by 812,713bps to -13,591.00% in 2025.
  • Its Net Margin stands at -13,591.00% for Q3 2025, versus -12,166.41% for Q2 2025 and -5,228.80% for Q1 2025.